Tomov S, Tzingilev D, Gorchev G, Velkova A, Vesselinova T, Popovska S
Clinic of Gynecologic Oncology, Oncologic Center, Medical University, Pleven, Bulgaria.
J BUON. 2005 Apr-Jun;10(2):241-6.
To introduce a quantitative method for determination of epidermal growth factor receptor (EGFR) expression in tissue samples taken from normal ovaries, benign and malignant ovarian tumours, convenient for routine tests.
About 1g of tissue was taken intraoperatively from 136 patients; 105 of them had histologically verified ovarian tumours (64 malignant, 42 benign) and 30 had normal ovaries. The tissue was frozen, preserved and transported in liquid nitrogen (-196 degrees C). The level and frequency of EGFR expression were determined by radioligand method, utilizing (125)I-labeled epidermal growth factor (EGF) and recombinant human EGF. The results were obtained as fmol bound EGF per mg protein from the membrane fraction. All samples having expression >/=3 fmol/mg were considered as positive.
The frequency of EGFR expression was 52% (70/136 patients), with a mean level of expression 45 +/-11 fmol/mg (range 0-1332). From the EGFR-positive patients with malignant ovarian tumours 21 (62%) had progressive disease (PD) while only 4 (13%) patients with negative EGFR had PD (p=0.001). The mean progression-free interval in the first group was 4 months, and in the second group it was 11 months (p=0.0028).
The proposed quanitative radioligand binding assay is easy to perform, rapid and well reproducible, and we recommend it for routine clinical use.
介绍一种定量方法，用于测定取自正常卵巢、良性和恶性卵巢肿瘤的组织样本中的表皮生长因子受体（EGFR）表达，便于常规检测。
术中从136例患者身上获取约1g组织；其中105例经组织学证实患有卵巢肿瘤（64例恶性，42例良性），30例卵巢正常。组织在液氮（-196℃）中冷冻、保存和运输。利用（125）I标记的表皮生长因子（EGF）和重组人EGF，通过放射性配体法测定EGFR表达的水平和频率。结果以膜分离物中每毫克蛋白质结合的EGF的飞摩尔数表示。所有表达≥3飞摩尔/毫克的样本被视为阳性。
EGFR表达频率为52%（70/136例患者），平均表达水平为45±11飞摩尔/毫克（范围0-1332）。在EGFR阳性的恶性卵巢肿瘤患者中，21例（62%）有疾病进展（PD），而EGFR阴性的患者中只有4例（13%）有PD（p=0.001）。第一组的平均无进展生存期为4个月，第二组为11个月（p=0.0028）。
所提出的定量放射性配体结合测定法易于操作、快速且重复性好，我们推荐将其用于常规临床应用。
